Compounding Pharmaceutical Companies Vaccines 
pharmaphorum
FEBRUARY 9, 2022
In this article, Ben Hargreaves looks into the promise of cancer vaccines and how this treatment modality may offer advantages over existing immunotherapies in the oncology sector. The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment.
pharmaphorum
DECEMBER 16, 2022
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MARCH 11, 2024
In a review on fungal-contaminated compounded pharmaceuticals and medical devices, researchers have described how the contamination of these products can be due to breaches in sterile compounding procedures. Ahmed et al.
Pharmaceutical Technology
FEBRUARY 14, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on I nnovation in Pharmaceuticals: Isotropically modified heterocyclic compounds. However, not all innovations are equal and nor do they follow a constant upward trend.
pharmaphorum
OCTOBER 21, 2022
The UK company reveals the results from a partner-led survey to discover the rates of vaccination for adults, why levels are lower than expected, and what can be done to improve this. The result of the improving knowledge of vaccines’ role in society initially led to a rise in interest in receiving a COVID-19 vaccine.
pharmaphorum
AUGUST 27, 2020
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies. In the UK, structural problems of the AIM market have compounded these problems by driving institutional investors away from relatively illiquid shares.
Pharma Marketing Network
AUGUST 26, 2020
In office/in person sales promotion, the staple of pharmaceutical company activities, is simply not possible today with interactions reduced to the sporadic video or to telephone engagement. This will result in permanent shifts in how HCPs and patients interact with pharmaceutical companies.
Expert insights. Personalized for you.
134 
Let's personalize your content